Synterex is now part of TransPerfect. The Massachusetts firm, known for its medical writing and AI document tools, has been acquired. The price was not made public. Synterex’s AgileWriter.ai platform and its staff, led by founder Jeanette Towles, join TransPerfect Life Sciences.
Drug and biotech companies face a tough job. Writing and managing clinical and regulatory documents takes time and carries risk. Synterex’s AgileWriter.ai uses artificial intelligence to automate parts of writing, review, and document management. It keeps the traceability and controls needed for strict compliance. Now, TransPerfect will fold this technology into its global setup and medical writing teams. The goal is to cut down on handoffs between writers, tech, and content managers.
Synterex is recognized as both a disability-owned and woman-owned business, reflecting a commitment to diversity in the life sciences consulting sector.
AI and human review in regulated content
Automation can speed up document prep. But drug and device rules demand tight checks for accuracy and traceability. Synterex blends scientific and medical writing with automation and natural language processing. Human judgment stays at the center, even as AI takes on more grunt work. Synterex, both disability-owned and woman-owned, will keep running as a division of TransPerfect Life Sciences. Its leaders and team will stay on after the deal, according to a company statement on October 1, 2026.
TransPerfect is not splitting tech from science and regulatory work. Instead, it wants a single process from writing to regulatory submission. This deal pushes TransPerfect further up the document chain. Clients may now move content from first draft to final submission in one workflow. The company announcement says the combined offering aims for a seamless workflow, cutting out wasted steps and manual handoffs.
Building out services and reach
TransPerfect Life Sciences already offers clinical trial tech, regulated content management, pharmacovigilance, translation, and call center support. Adding Synterex’s tools and know-how will boost these services across more document types and therapy areas. Jeanette Towles said Synterex was built on the idea that “deep scientific expertise, agile ways of working, and responsible technology can improve how clinical and regulatory content is developed.” She said joining TransPerfect gives access to bigger infrastructure and more clients, while keeping Synterex’s focus on quality and human review.
The acquisition aligns with a broader industry trend to connect AI tools with regulated life-sciences workflows, aiming to reduce handoffs between writing, technology, and content-management functions in clinical and regulatory document production.
Life sciences companies are now testing generative AI and automation to speed up clinical and regulatory work. Medical writing could see big gains from automation. But only if compliance and quality controls stay strong. TransPerfect’s president and co-CEO Phil Shawe says the company’s approach is to mix automation with expert knowledge, not to treat tech and science as separate silos.
Industry consolidation is picking up. Other recent deals include the reported earlier buyout of Theravance by Zymeworks. TransPerfect’s move to bring in Synterex’s AI platform and writing team shows a clear plan to offer smoother, tech-enabled service to clients worldwide.
TransPerfect operates in over 150 cities and works in more than 200 languages. Buying Synterex is a calculated step to grow its reach and skills in regulated content. Silverwood Partners, Mintz, and DLA Piper LLP advised on the deal. The move answers rising demand for integrated, AI-powered solutions in life sciences paperwork. But it’s the focus on human review and scientific care that will decide if this integration really helps clients handle pharma and biotech rules.
